Overlooked in the hubbub surrounding the U.S. Supreme Court hearings over the Affordable Care Act this week were a pair of patent decisions that could have similarly huge implications.
The Supremes issued a unanimous decision last week on March 20 to strike down a pair of patents covering medical testing methods in Mayo v. Prometheus, ruling that medical tests relying on the relationship between drug dosages and treatment are non-patentable because they describe "laws of nature."